Vertex Corrects Cystic Fibrosis Data; Shares Tumble

Vertex Pharmaceuticals Inc released corrected data involving its cystic fibrosis treatments on Tuesday that lowered the number of patients who showed certain levels of improved lung function, sending its ...

Vertex (VRTX) reported interim data on a Phase II study targeting Cystic Fibrosis, which affects 30,000 in the United States and 70,000 worldwide. Previously, the company's KALYDECO drug - which won FDA approval in January - could only be used to treat about 4% of those patients.

While new medicines make progress (or fail) in clinical trials every day with varying levels of attention from the public and press, this week’s

By Rod Raynovich: Vertex Pharmaceuticals Gives Biotech Sector A Turbo Boost

By Brian L.

By Prohost Biotech:On Monday May 7, 2012, Vertex (VRTX) announced an interim analysis of data from an ongoing Phase 2 study of VX-809 in combination with Kalydeco (ivacaftor).

Robert Weinstein submits: The Way means inducing the people to have the same aim as the leadership, so that they will share death and share life, without fear of danger. -- Sun Tsu, The Art of War. Vertex Pharmaceuticals Incorporated (VRTX) of Cambridge, MA was up strongly today to close at $49.95 a share.

By Scott Matusow:Vertex Pharmaceuticals (VRTX) engages in the discovery, development, and commercialization of small molecule drugs for the treatment of serious diseases worldwide.